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Abstract
Introduction Anti-adhesion molecule therapy prevents
leukocytes from extravasating. During exaggerated
inflammation, this effect is wanted; however, during infection,
blocking diapedesis may be detrimental. In this study, therefore,
the potential risks of anti-L-selectin antibody therapy were
evaluated in a primate model of sepsis.
Methods Sixteen baboons were anesthetized and randomized
into two groups. The experimental group received 2 mg/kg of
the anti-L-selectin antibody HuDREG-55 and the control group
received Ringer's solution prior to the onset of a 2 h infusion of
Escherichia coli (1–2 × 109 colony forming units (CFU)/kg body
weight). Serial blood samples were drawn over a 72 h period for
the measurement of tumour necrosis factor-α, IL-6 and
polymorphonuclear elastase. In addition, blood gas analysis,
hematology and routine clinical chemistry were determined to
monitor cardiovascular status, tissue perfusion and organ
function.
Results The three-day mortality rate and the mean survival time
after E. coli-induced sepsis were similar in the two groups. The
bacterial blood CFU levels were significantly higher in the
placebo group than in the anti-L-selectin group. Other
parameters measured throughout the 72 h experimental period,
including the cardiovascular, immunologic, and hematologic
responses as well as indicators of organ function and tissue
perfusion, were similar in the two groups, with the exception of
serum creatinine and mean arterial pressure at 32 h after E. coli
challenge.
Conclusion Anti-L-selectin therapy did not adversely affect
survival, promote organ dysfunction or result in major side
effects in the baboon sepsis model. Additionally, as anti-L-
selectin therapy improved the bacterial clearance rate, it
appears that this therapy is not detrimental during sepsis. This is
in contrast to previous studies using the baboon model, in which
antibody therapy used to block CD18 increased mortality.
Introduction
The interaction of neutrophils with endothelial cells is a key
event in the host response to inflammatory stimuli. While ben-
eficial in cases of infection, this same neutrophil-endothelial
cell interaction can lead to tissue injury, especially in condi-
tions associated with excessive inflammatory responses. L-
selectin is constitutively present on leukocytes and rapidly
shed upon activation. This molecule is actively involved in the
early phases of neutrophil binding to the endothelium. Specif-
ically, L-selectin initiates the initial phase of neutrophil adhe-
sion to the endothelium, while the subsequent steps involve
the β-integrins (CD11/CD18), which strengthen the adhesion
of neutrophils to the endothelium and mediate the ensuing
extravasation of neutrophils into tissues such as the lung [1,2].
Neutrophil products, such as reactive oxygen species and pro-
teases, can cause tissue destruction. Thus, by inhibiting neu-
trophil extravasation, tissue damage could be avoided. As the
first step in the process of neutrophil adhesion is mediated by
CFU = colony forming units; IL = interleukin; PMN = polymorphnuclear granulocyte; SVR = systemic vascular resistance; TNF = tumour necrosis 
factor.Critical Care    Vol 9 No 6    Redl et al.
R736
the members of the selectin family (L-, E-, and P-selectin), neu-
trophil adhesion to the endothelium may be blocked by admin-
istration of anti-L-selectin antibodies. These anti-L-selectin
antibodies could reduce organ injury by decreasing neutrophil
accumulation in different organs during the inflammatory
response. Animal studies support this notion, showing that the
administration of neutralizing monoclonal antibodies, which
recognize functional epitopes of L-selectin, reduces organ
injury following ischemia-reperfusion [3], hemorrhage [4] and
sepsis [5]. Our recent results in a baboon trauma model show
that HuDREG-55 (a humanized monoclonal antibody specific
for L-selectin) administered during post-traumatic resuscita-
tion improves long-term survival [6].
These observations are in general agreement with previous
inhibitor studies using anti-L-selectin therapies that included
antibodies [3-5], as well as soluble molecules, such as low
molecular weight carbohydrates like sialyl Lewisx  [7]. The
microcirculatory protection provided by HuDREG-55 appears
to be secondary to a functional blockade of the L-selectin mol-
ecule. A blockade of the L-selectin molecule is associated with
three possible positive effects: decrease in L-selectin medi-
ated polymorphonuclear granulocyte (PMN) rolling [1], pre-
vention of L-selectin-mediated signal transduction [8], and
reduction in PMN aggregation [9]. All three of these positive
effects of L-selectin blockade could result in less endothelial
damage due to activated PMNs. However, despite the positive
effects of L-selectin blockade described in these various stud-
ies, blockade of leukocyte adhesion molecules may exhibit
potential negative side effects [10], including the possibility of
an increased risk of infection.
Anti-L-selectin antibody therapy interferes with the interaction
of leukocytes with the endothelium at the early stage of leuko-
cyte rolling. Thus, anti-L-selectin antibody therapy should the-
oretically decrease leukocyte recruitment to sites of infectious
as well as non-infectious inflammation. In infectious inflamma-
tion, decreased PMN recruitment to tissue could create the
risk of impaired defense in patients with bacterial or viral infec-
tions. Indeed, administration of antibodies to ICAM has been
shown to increase morbidity and mortality in the baboon model
of sepsis [11].
It is not known whether anti-L-selectin antibody therapy exerts
similar detrimental actions. This therapy might negatively influ-
ence pathological events in sepsis by interfering with phago-
cyte function, thus decreasing bacterial clearance.
Subsequently, this may increase organ damage and adversely
affect survival. To evaluate these potential risks of anti-L-selec-
tin antibody therapy, we tested the effect of L-selectin block-
ade in a non-human primate model of Escherichia coli sepsis.
In order to simulate the worst case scenario of the trauma
patient with incipient sepsis on antibody therapy, we adminis-
tered the anti-L-selectin antibody just prior to the induction of
E. coli-induced severe sepsis. We are aware, however, that
the animals were not and could not be subjected to trauma
prior to the induction of severe sepsis.
Materials and methods
Animals
Sixteen adult male Chacma baboons of the strain Papio ursi-
nus weighing between 18 to 22 kg each were used in the
study. These healthy animals were kept in quarantine for 3
months prior to the study and fasted overnight before the
experiments. The experimental protocol was approved by the
Institutional Animal Care Use Committee at Biocon Research
(Pretoria, South Africa) and the animals were treated accord-
ing to National Institute of Health guidelines.
Instrumentation
Animals were anesthetized with 6 to 8 mg/kg of intramuscu-
larly injected ketamine hydrochloride (Ketalar®, Parke Davis
Co., Ann Arbor, MI, USA), and placed in the supine position.
For spontaneous respiration, a special setup of low continu-
ous positive airway pressure (1 to 2 mmHg) respiration was
used. FiO2 was adjusted at 0.25 ± 0.02. Anesthesia was main-
tained with pentobarbital (1 to 3 mg/kg/hour) using a servo-
controlled mechanism based on the electroencephalogram.
A 7F Swan-Ganz catheter (Arrow, Reading, USA) was
inserted through the femoral vein and advanced into the pul-
monary artery. This catheter was also used to monitor temper-
ature. A polyvinyl catheter was introduced into the right
brachial artery for arterial sampling and pressure monitoring.
Catheters were connected to pressure transducers coupled
to Lifescope II monitors (Nikon, Kohden, Tokyo, Japan). A triple
lumen catheter (Arrow, Reading, USA) was inserted into the
right brachial vein for anesthesia maintenance, administration
of medication and for venous blood sampling. This catheter
was removed at the end of the acute study period (6 h after the
start of E. coli infusion). Cardiac output measurements were
obtained using Edwards COM-2™ (Baxter, Glendale, CA).
After placement, the catheters were connected to a recording
device and baseline data reflecting the normal simian values
were collected. The animals were monitored continuously for
an additional 6 h, and the catheters were then placed in a sub-
cutaneous pouch. At 10, 24, 32, 48 and 72 h after the admin-
istration of E. coli bacteria the animals were again
anesthetized with intramuscularly injected ketamine as
described above. Subsequently, the catheters were recon-
nected to recording devices, and cardiopulmonary variables
were measured again. Ringer's solution was administered at 5
ml/kg/h at baseline, increased to 20 ml/kg/h during sepsis and
further adjusted to maintain pulmonary arterial wedge pres-
sure at or above 6 mmHg. In several animals this value could
be maintained; however, some of them were too ill to be able
to achieve this goal. Although this model does not include any
absolute fluid loss, sepsis will cause a relative fluid depletion
due to fluid shifts into third space. At the end of each studyAvailable online http://ccforum.com/content/9/6/R735
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period, the catheters were disconnected and secured in the
subcutaneous pouch. No anesthetics were administered dur-
ing these measurement intervals, and the animals stayed
awake in their cages. At the end of the study period, the ani-
mals were again anesthetized with intramuscularly injected
ketamine for measurements and were then sacrificed by
administration of an overdose of pentobarbital.
Study protocol
After cardiopulmonary stability had been achieved, E. coli bac-
teria were infused according to our previously described tech-
nique [12]. Briefly, 1 to 2 × 109 colony forming units of live E.
coli  per kilogram (Hinshaw's strain B7 (086a:61, ATCC
33985)) were infused intravenously over a 2 h period. Antibi-
otic therapy (gentamycin 4 mg/kg) was administered at 2, 6
and then every 12 h. The animals were observed for a 72 h
period.
The animals were randomly assigned to one of two experimen-
tal groups (n = 8 per group). Group 1 received a single intra-
venous bolus injection of 2 mg/kg anti-L-selectin antibody (2.8
mg/ml) and group 2 received 0.72 ml/kg of Ringer's solution
as placebo prior to the onset of the 2 h infusion of E. coli. The
anti-L-selectin antibody used in the study was a recombinant
humanized IgG4 isotype antibody also known as HuDREG55.
The placebo group received only Ringer's solution, as an ade-
quate isotype-matched control antibody of clinical-grade qual-
ity (same species, same isotype) was not available.
Blood sample measurements
Heparinized blood samples were drawn at 0.5, 2, 4, 6, 10 and
24 h after start of E. coli infusion for blood cultures. Different
Figure 1
Survival rate in baboons treated with 2 mg/kg anti-L-selectin antibody  (L-SEL-Ab, n = 8) or the equivalent volume dose of Ringer's solution (n  = 8) with the pre-defined 72 h observation period after onset of  Escherichia coli sepsis Survival rate in baboons treated with 2 mg/kg anti-L-selectin antibody 
(L-SEL-Ab, n = 8) or the equivalent volume dose of Ringer's solution (n 
= 8) with the pre-defined 72 h observation period after onset of 
Escherichia coli sepsis.
Figure 2
Colony forming units (CFU) in blood of baboons treated with 2 mg/kg  anti-L-selectin antibody (L-SEL-Ab, n = 8) or the equivalent volume  dose of Ringer's solution (n = 8) after onset of 2 h infusion (t = 0–2 h)  of live Escherichia coli Colony forming units (CFU) in blood of baboons treated with 2 mg/kg 
anti-L-selectin antibody (L-SEL-Ab, n = 8) or the equivalent volume 
dose of Ringer's solution (n = 8) after onset of 2 h infusion (t = 0–2 h) 
of live Escherichia coli. Mean ± SE; asterisk represents p < 0.05.
Figure 3
Kinetics of the inflammation parameters white blood cell count and  elastase Kinetics of the inflammation parameters white blood cell count and 
elastase. (a) Time course of white blood cell (WBC) counts in baboons 
treated with 2 mg/kg anti-L-selectin antibody (L-SEL-Ab, n = 8) or the 
equivalent volume dose of Ringer's solution (n = 8) after onset of 2 h 
infusion (t = 0–2 h) of live Escherichia coli. (b) Time course of plasma 
elastase concentrations in baboons treated with 2 mg/kg L-SEL-Ab (n 
= 8) or the equivalent volume dose of Ringer's solution (n = 8) after 
onset of 2 h infusion (t = 0–2 h) of live E. coli.Critical Care    Vol 9 No 6    Redl et al.
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lines were used for drawing blood samples and infusion of the
bacteria.
Serum samples were prepared from blood drawn at -0.5 (half
an hour before infusion of E. coli), 1, 2, 6, 10, 24, 32, 48 and
72 h to determine levels of tumour necrosis factor (TNF)-α, IL-
6, and PMN elastase. TNF-α levels were determined by an
enzyme-linked immunosorbent assay (ELISA) method. IL-6
was determined using an immunoassay on microplates. In this
assay, a mouse monoclonal antihuman IL-6 antibody (5E1)
was used for coating and a rabbit polyclonal antihuman IL-6
was used as the detecting antibody (antibodies kindly pro-
vided by WA Buurman, Maastricht, the Netherlands). Recom-
binant human IL-6 served as standard (kindly provided by P
Mayer, Novartis, Vienna, Austria). PMN-elastase was deter-
mined with an enzyme immunoassay based on the radioimmu-
noassay system published previously [13].
Quantitative blood cultures were collected in Roche blood cul-
ture medium (Roche, Basel, Switzerland) and further proc-
essed, as described elsewhere [14].
Further blood samples were drawn for blood gas analysis,
hematology and routine clinical chemistry. Commercially avail-
able kits were used to measure alanine aminotransferase, cre-
atinine, and total protein (Roche, Basel, Switzerland) or lactate
(Boehringer Mannheim, Mannheim, Germany). A Cobas Fara
centrifugal analyzer (Roche, Basel, Switzerland) was used for
these measurements. Arterial blood pO2, pCO2, pH, bicarbo-
nate, hemoglobin, and standard base excess were determined
(Radiometer ABL 330, Copenhagen, Denmark). Total leuko-
cyte, erythrocyte and platelet count, hemoglobin and hemat-
ocrit were determined using a Coulter T890 counter (Coulter
Electronics Inc., Hialeah, FL, USA).
Statistics
Data are presented as mean ± standard error. The statistical
evaluation between groups was performed, if not stated other-
wise, using Kruskal-Wallis. The Bonferroni-Holm correction
was used for repeated application of a statistical test. Survival
data are shown in a Kaplan-Meier curve, and differences were
calculated using the log-rank test.
Results
Survival
Following a period of stabilization after surgical preparation,
baseline values for cardiovascular variables were similar in
both groups prior to E. coli infusion and the concomitant injec-
tion of the anti-L-selectin antibody or the equivalent volume of
Ringer's solution.
Four of eight baboons receiving Ringer's solution (placebo)
died within the 72 h observation period, while five of eight ani-
mals receiving anti-L-selectin antibody treatment died (Figure
1). The mean survival time did not differ between placebo- and
anti-L-selectin-treated baboons (57.3 ± 5.7 and 57.0 ± 6.7 h,
respectively).
Colony forming units
Baboons in the placebo and in the anti-L-selectin group
received the same amount of live E. coli (1.64 ± 0.03 and 1.61
± 0.04 × 109 colony forming units (CFU)/kg). At the end of the
2 h infusion of E. coli, the CFU count in the blood was signifi-
cantly higher in the placebo group than in the anti-L-selectin
group (124 ± 103 versus 4.5 ± 3.6 × 103/ml; p < 0.05) (Fig-
ure 2).
White blood cells/elastase/erythrocytes/platelets/TNF-
α/IL-6
Leukocyte counts did not differ significantly between the pla-
cebo and anti-L-selectin groups (Figure 3a), during leucopenia
or during the leucocytosis period (at about 24 h). Similarly,
PMN elastase in plasma, an indicator of leucocyte activation
status, did not differ significantly between the groups (Figure
3b). Erythrocyte and platelet counts did not differ between the
two groups either (data not shown).
Table 1
TNF-α and IL-6 in baboons infused with live Escherichia coli and treated with placebo or anti-L-selectin antibody
Time (hours)
- 0 . 5 0 1 2 4 61 0 2 4 3 24 8 7 2
TNF-α (pg/ml)
Placebo 0 ± 0 2 ± 2 5,950 ± 1,762 6,325 ± 2,026 244 ± 71 55 ± 18 28 ± 15 21 ± 7 19 ± 7 8 ± 5 0 ± 0
L-SEL-Ab 6 ± 4 1 ± 1 9,048 ± 2,227 6,648 ± 1,465 236 ± 45 60 ± 9 39 ± 7 33 ± 11 34 ± 11 37 ± 15 39 ± 15
IL-6 (pg/ml)
Placebo 4 ± 3 17 ± 8 2,059 ± 263 6,968 ± 718 7,331 ± 963 6,082 ± 832 5,364 ± 773 3,032 ± 900 1,921 ± 860 2,435 ± 
1,635
896 ± 73
L-SEL-Ab 13 ± 5 6 ± 4 2,270 ± 665 7,392 ± 802 7,490 ± 773 7,075 ± 765 5,952 ± 500 3,547 ± 644 2,550 ± 689 1,684 ± 761 907 ± 77
IL-6, interleukin-6; L-SEL-Ab, anti-L-selectin antibody; TNF-α, tumor necrosis factor-α.Available online http://ccforum.com/content/9/6/R735
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TNF-α increased in both groups during the infusion of E. coli
but was not significantly different between the two groups
(Table 1). IL-6 increased after the onset of the E. coli infusion
and persisted throughout the observation period, but did not
differ significantly between the two groups (Table 1).
Cardiovascular system
The time course of the various cardiovascular parameters
demonstrated no major difference between the two groups
regarding systemic vascular resistance (SVR). There was a
drop in SVR at the end of the infusion of E. coli in both groups,
followed by a decline at 24 h. Hemodynamic responses as
well as gas exchange data, including heart rate, mean arterial
pressure, cardiac output, pulmonary artery pressure, pulmo-
nary arterial wedge pressure, peripheral vascular resistance,
arterial pO2, and arterial pCO2, are summarized in Table 2. The
only significant cardiovascular difference was found in mean
arterial pressure at 32 h, but was not reflected in cardiac out-
put and SVR.
Tissue perfusion, as reflected by arterial base excess and lac-
tate, did not significantly differ between the two groups (Table
3). The trend in fluid infusion requirements was higher in the
placebo group than in the antibody group, but this was not sta-
tistically significant (Table 4). Accordingly, there were no dif-
ferences between the groups in hematocrit or total protein
concentrations (Table 4).
Table 2
Hemodynamic responses in baboons infused with live Escherichia coli and treated with placebo or anti-L-selectin antibody
Time (hours)
- 0 . 50 1 2 4 61 02 43 24 87 2
Heart rate 
(beats/minute)
Placebo 124 ± 3 125 ± 3 156 ± 9 171 ± 7 170 ± 5 160 ± 5 141 ± 7 142 ± 6 138 ± 9 139 ± 5 151 ± 11
L-SEL-Ab 122 ± 5 121 ± 4 160 ± 9 177 ± 7 165 ± 3 168 ± 6 151 ± 5 142 ± 15 141 ± 14 143 ± 10 158 ± 10
MAP (mmHg)
Placebo 113 ± 6 122 ± 3 102 ± 8 72 ± 5 103 ± 5 117 ± 6 95 ± 9 75 ± 11 75 ± 6 65 ± 11 70 ± 6
L-SEL-Ab 119 ± 4 122 ± 3 104 ± 6 72 ± 5 97 ± 5 111 ± 6 85 ± 10 51 ± 8 51 ± 7 61 ± 12 79 ± 8
CO (l/minute)
Placebo 3.1 ± 0.2 3.2 ± 0.2 4.3 ± 0.4 4.6 ± 0.4 4.4 ± 0.4 4.2 ± 0.4 2.5 ± 0.2 3.5 ± 0.4 4.2 ± 0.3 3.6 ± 0.3 3.7 ± 0.2
L-SEL-Ab 3.1 ± 3.1 3.1 ± 3.1 4.8 ± 4.8 5.5 ± 5.5 4.8 ± 4.8 4.6 ± 4.6 2.5 ± 2.5 3.0 ± 3.0 3.8 ± 3.8 3.6 ± 3.6 3.8 ± 3.8
MPAP (mmHg)
Placebo 13 ± 1 14 ± 1 14 ± 1 13 ± 1 14 ± 2 18 ± 2 17 ± 3 17 ± 2 18 ± 3 15 ± 1 16 ± 3
L-SEL-Ab 13 ± 1 13 ± 1 13 ± 1 14 ± 1 14 ± 1 18 ± 1 16 ± 1 16 ± 2 16 ± 1 16 ± 1 15 ± 3
PWP (mmHg)
Placebo 3.5 ± 0.4 3.6 ± 0.5 4.4 ± 0.8 4.5 ± 1.0 4.8 ± 0.9 5.4 ± 0.8 1.4 ± 0.6 1.5 ± 0.5 3.5 ± 0.3 2.0 ± 0.7 1.5 ± 1.0
L-SEL-Ab 4.6 ± 0.7 4.5 ± 0.6 4.8 ± 0.6 5.5 ± 0.9 4.6 ± 0.8 4.9 ± 0.8 2.9 ± 0.6 2.8 ± 0.4 2.7 ± 0.4 3.6 ± 0.9 3.7 ± 0.3
PVR (dyn s cm-5)
Placebo 264 ± 21 258 ± 16 180 ± 11 160 ± 17 180 ± 20 265 ± 41 542 ± 112 399 ± 80 285 ± 58 292 ± 22 301 ± 78
L-SEL-Ab 220 ± 20 223 ± 18 142 ± 22 124 ± 15 162 ± 21 243 ± 30 441 ± 58 362 ± 50 296 ± 27 267 ± 25 279 ± 70
arterial pO2 
(mmHg)
Placebo 100.4 ± 6.8 101.5 ± 6.9 97.7 ± 5.2 104.8 ± 4.5 105.0 ± 4.3 100.2 ± 4.3 88.2 ± 2.5 84.7 ± 4.6 76.7 ± 6.4 73.1 ± 7.0 63.4 ± 6.5
L-SEL-Ab 101.9 ± 5.9 102.2 ± 4.4 105.0 ± 6.3 109.9 ± 4.0 105.9 ± 5.7 103.6 ± 6.0 91.0 ± 5.7 89.1 ± 5.4 82.2 ± 3.5 88.7 ± 7.5 77.6 ± 8.3
arterial pCO2 
(mmHg)
Placebo 48.8 ± 1.1 46.4 ± 1.0 45.0 ± 1.2 41.1 ± 1.2 34.6 ± 2.3 36.3 ± 0.9 33.2 ± 1.1 33.9 ± 1.9 34.1 ± 2.4 40.5 ± 3.2 45.7 ± 3.3
L-SEL-Ab 43.7 ± 1.5 43.1 ± 1.5 40.9 ± 0.4 39.1 ± 0.9 35.0 ± 1.7 34.5 ± 0.9 28.9 ± 2.3 31.5 ± 2.3 33.0 ± 3.4 35.3 ± 4.3 40.7 ± 6.1
arterial pCO2, arterial partial carbondioxide pressure; arterial pO2, arterial partial oxygen pressure; CO, cardiac output; L-SEL-Ab, anti-L-selectin 
antibody; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; PWP, pulmonary arterial wedge pressure; PVR, peripheral 
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Organ function
Kidney and liver function, as reflected by blood urea nitrogen
and alanine transferase, respectively, were similar in the two
groups (Table 5). The anti-L-selectin group, however, showed
significantly higher concentrations of serum creatinine at 48 h
compared to the placebo group (p = 0.047). This potential evi-
dence of kidney dysfunction was not histomorphologically
confirmed. The trend in urine volume was even higher in the
anti-L-selectin group, although not significant (p > 0.05, Table
5).
Arterial oxygen pressure and lung wet weight (14.6 ± 1.2 ver-
sus 15.1 ± 2.3 g/kg body weight) were used as indicators of
pulmonary function. No significant differences were found
between the placebo and anti-L-selectin group using either of
these markers of lung injury.
Discussion
Adhesion molecules play an important role in the interaction
between leukocytes and the endothelium in acute inflamma-
tion in conditions such as traumatic-hypovolemic shock [4],
gut ischemia-reperfusion [15], or myocardial infarction [3].
Although some studies have found beneficial effects [16] or
no adverse events [17] in inflammatory conditions associated
with septic foci using anti CD11/18 antibodies, there is still
major concern regarding the use of anti-adhesion therapy in
septic situations. A combination of anti-E/L-selectin resulted in
elevations in IL-6, IL-8, and Tumour Necrosis Factor Receptor-
1 (TNFR-1) when used in a septic model of heat killed E. coli
followed by live E. coli [18]. On the other hand, administration
of anti-L-selectin in an intravenous E. coli model was beneficial
[19]. This group could show, however, that the route of infec-
tion is important for the efficacy of the treatment. Anti-L-selec-
Table 3
Tissue perfusion parameters in baboons infused with live Escherichia coli and treated with placebo or anti-L-selectin antibody
Time (hours)
-0.5 0 1 2 4 6 10 24 32 48 72
aBE (mEQ/l)
Placebo 2.7 ± 0.5 4.0 ± 0.6 2.4 ± 0.3 0.8 ± 0.4 -0.4 ± 0.5 -0.4 ± 0.5 -3.4 ± 0.9 -6.6 ± 0.9 -2.6 ± 1.3 3.1 ± 2.6 7.9 ± 0.6
L-SEL-Ab 4.0 ± 0.9 4.3 ± 0.9 3.1 ± 0.9 0.5 ± 1.0 -0.7 ± 1.2 -0.8 ± 1.0 -5.3 ± 1.7 -10.1 ± 2.6 -4.8 ± 2.8 2.2 ± 2.5 7.3 ± 2.1
Lactate (mmol/l)
Placebo 3.4 ± 0.8 3.3 ± 0.8 2.4 ± 0.4 3.5 ± 0.4 5.2 ± 0.4 4.9 ± 0.4 7.3 ± 0.7 12.1 ± 1.0 7.8 ± 0.8 6.7 ± 0.8 5.2 ± 0.6
L-SEL-Ab 3.9 ± 0.9 3.9 ± 0.9 1.9 ± 0.2 4.3 ± 0.7 6.1 ± 0.9 6.1 ± 0.7 9.2 ± 1.4 14.5 ± 1.9 9.8 ± 1.0 6.7 ± 0.8 6.7 ± 1.1
aBE, arterial base excess; L-SEL-Ab, anti-L-selectin antibody.
Table 4
Fluid infusion requirements
Time (hours)
- 0 . 5 01246 1 0 2 4 3 2 4 8 7 2
Ringer (ml/kg BW)
Placebo 1 ± 0 7 ± 0 21 ± 2 40 ± 4 92 ± 4 134 ± 6 135 ± 6 159 ± 7 186 ± 11 223 ± 13 250 ± 19
L-SEL-Ab 1 ± 0 7 ± 0 20 ± 2 38 ± 4 90 ± 6 130 ± 9 131 ± 10 157 ± 11 189 ± 16 204 ± 9 219 ± 16
Hematocrit (%)
Placebo 42.1 ± 1.3 40.3 ± 1.1 37.8 ± 1.2 35.7 ± 1.4 36.4 ± 1.6 36.6 ± 1.4 40.8 ± 1.5 35.4 ± 2.3 29.1 ± 2.0 27.5 ± 1.6 26.0 ± 2.5
L-SEL-Ab 40.7 ± 1.6 38.6 ± 1.7 37.8 ± 1.5 34.8 ± 1.3 35.5 ± 1.4 36.5 ± 1.5 40.4 ± 1.8 34.3 ± 1.5 31.4 ± 1.6 29.7 ± 1.2 28.6 ± 2.2
Protein (g/100 ml)
Placebo 6.5 ± 0.2 6.1 ± 0.1 5.3 ± 0.2 4.5 ± 0.2 4.2 ± 0.1 4.1 ± 0.1 4.8 ± 0.1 4.6 ± 0.1 4.4 ± 0.2 4.1 ± 0.3 4.5 ± 0.4
L-SEL-Ab 6.0 ± 0.2 5.7 ± 0.2 5.0 ± 0.1 4.1 ± 0.1 4.0 ± 0.1 4.0 ± 0.2 4.5 ± 0.2 4.1 ± 0.2 4.0 ± 0.2 4.0 ± 0.3 4.4 ± 0.4
Accumulation amount of Ringer's solution over time, hematocrit and total plasma protein concentration in baboons infused with live Escherichia coli and treated with 
either placebo or anti-L-selectin antibody (L-SEL-Ab). BW = body weight.Available online http://ccforum.com/content/9/6/R735
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tin treatment worsened the late course of the intrabronchial E.
coli disease [19]. A similar model using intrabronchial E. coli
in rats showed that treatment with anti-ICAM-1 led to
increased mortality [20]. Anti-CD11b treatment did not
change mortality rates, although harmful effects could not be
excluded [20]. These effects were dependent on the dose of
the antibodies. Thus, one has to bear in mind that experimental
protocol differences may be a reason for mixed published
results from different studies. Though not primarily intended
for use in sepsis, anti-adhesion antibodies infused for other
reasons (trauma, shock, ischemia/reperfusion) could be
present at the onset of septic events. Interestingly, anti-L-
selectin antibody therapy in the present study did not
adversely affect the 3 day mortality rate or the mean survival
time, indicating that it had no overall adverse effects on the
pathogenetic course of sepsis in this well established model
of baboon sepsis [12]. As this is a very severe model, acceler-
ating negative effects would have been especially expected if
anti-L-selectin treatment had been detrimental. As the model is
severe, however, worsening of the septic state could also be
hard to detect. Thus, detrimental effects may not be com-
pletely excluded by the study. On the other hand, no beneficial
effects were expected as this is a pure sepsis model. In this
case, anti-adhesion molecule treatment is not an option. It
could, however, be a possible treatment in a trauma situation,
where increased PMN extravasation is present. Sepsis is a
common complication during the post-traumatic course.
Therefore, this study focused on the safety issues of anti-L-
selectin during a possible post-traumatic sepsis.
In other studies, a decreased expression of cell surface L-
selectin was associated with worse outcome in septic trauma
patients or patients suffering from multiple trauma [21,22].
Reduced L-selectin levels lead to an increase in mortality after
sepsis [23]. Seidelin et al. [24] proposed a cutoff point of 470
ng/ml for the level of soluble L-selectin predicting survival in
septic patients. Moreover, this shedding can cause an
increase in TNF-α receptors on PMNs [25] and thereby poten-
tate the harmful actions of the PMNs. Furthermore, shedding
of L-selectin serves as a signalling event for increasing the res-
piratory burst activity, which could exaggerate tissue damage
[26]. Blocking L-selectin may, therefore, be beneficial not only
by inhibiting extravasation, but also by modulating signal trans-
duction pathways.
Studies with L-selectin knock-out mice have demonstrated a
reduction in lymph node trafficking, a process that is normally
required for proper generation of an immune response [27].
One may expect, therefore, that treatment with anti-L-selectin
antibody would cause marked immune suppression. In con-
trast to these expectations, however, recent experiments have
shown that mice treated with anti-L-selectin antibody can still
effectively eliminate viruses [28] and parasites [29]. Adminis-
tration of an anti-L-selectin antibody resulted in a reduced pul-
monary injury in a sheep ischemia/reperfusion model but did
not reveal any influence on neutrophil functions like respiratory
burst [30]. This demonstrated a protective effect for second-
ary organ damage. Positively, the treatment did not inhibit the
ability of PMN to kill microorganisms. The small-molecule pan-
selectin-inhibitor TBC-1269 has been demonstrated to be
protective against neutrophil recruitment and to improve sur-
vival rates in a two-hit model of hemorrhagic shock with addi-
tional lipopolysaccharide challenge [31]. Another study in a
murine two-hit model of ischemia/reperfusion and cecal liga-
Table 5
Kidney and liver function
Time (hours)
- 0 . 50 1 2 4 6 1 02 43 24 8 7 2
Creatinine (µmol/l)
Placebo 86 ± 3 81 ± 5 78 ± 6 80 ± 6 93 ± 6 97 ± 11 133 ± 18 200 ± 48 189 ± 73 112 ± 10 96 ± 7
L-SEL-Ab 105 ± 6 96 ± 7 88 ± 7 93 ± 5 104 ± 6 109 ± 7 145 ± 16 240 ± 42 276 ± 65 226 ± 90a 121 ± 12
Urine output (ml/h)
Placebo nd 43.8 ± 11.0 31.9 ± 9.3 63.75 ± 29.0 111.3 ± 95.8 124.4 ± 34.3 84.4 ± 17.5 87.1 ± 27.2 80.8 ± 25.0 69.0 ± 12.6 nd
L-SEL-Ab nd 36.88 ± 11.1 38.1 ± 12.3 66.9 ± 26.4 161.9 ± 42.0 122.5 ± 41.1 94.4 ± 25.6 79.4 ± 16.4 55.0 ± 7.2 72.0 ± 7.3 nd
BUN (mg/dl)
Placebo 12.7 ± 1.2 12.1 ± 1.3 13.2 ± 1.3 12.2 ± 1.4 11.7 ± 1.4 11.9 ± 1.2 17.9 ± 2.0 30.8 ± 1.8 34.1 ± 4.3 38.0 ± 7.3 30.5 ± 4.3
L-SEL-Ab 13.7 ± 2.2 13.6 ± 2.2 11.6 ± 1.8 12.8 ± 2.1 11.9 ± 2.2 12.4 ± 2.0 16.4 ± 2.0 32.7 ± 2.5 39.7 ± 3.4 41.9 ± 6.3 31.6 ± 4.1
ALT (U/l)
Placebo 12 ± 3 12 ± 2 9 ± 2 8 ± 2 25 ± 11 46 ± 20 78 ± 27 112 ± 21 93 ± 24 68 ± 12 71 ± 18
L-SEL-Ab 13 ± 2 10 ± 2 7 ± 0 7 ± 2 13 ± 4 16 ± 5 37 ± 13 93 ± 35 110 ± 28 100 ± 26 100 ± 30
Organ function in baboons infused with live Escherichia coli and treated with either placebo or anti-L-selectin antibody. ap = 0.047.
ALT, alanine transferase; BUN, blood urea nitrogen; L-SEL-Ab, anti-L-selectin antibody; nd, not done.Critical Care    Vol 9 No 6    Redl et al.
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tion and puncture used the sialyl Lewisx analogue fucoidin, a
sulphated polymer of L-fucose. The study revealed that fucoi-
din attenuates selectin-mediated neutrophil adherence but not
neutrophil recruitment. Furthermore, fucoidin administration
resulted in improved morphologic pathology [32]. These data
could be a sign for the importance of selectins as cell signal-
ling molecules rather than their function in adhesion.
The findings of the current study further support the potential
safety of anti-L-selectin therapy in the presence of bacterial
infection. Interestingly, anti-L-selectin antibody administration
was associated with improved bacterial clearance. This was
demonstrated by a significant reduction of the CFU count in
blood in the anti-L-selectin group, although the amount of
infused E. coli/kg body weight was virtually identical in both
groups. The mechanism behind this intriguing observation is
not clear. A possible role for the reticuloendothelial system
and concomitant complement activation might be involved.
The role of L-selectin in this respect is, however, hard to deter-
mine from our data. One could speculate that the signal trans-
duction properties of L-selectin may play a role. These
properties could enhance the activity of the reticuloendothelial
system. This could enhance the clearance of the bacteria.
Moreover, certain signal transduction pathways could induce
complement activation. The complement system efficiently
kills bacteria. Therefore, both entities could lead to an
increased clearance of bacteria already during the infusion
phase. This finding is in concert with the fact that anti-L-selec-
tin did not negatively influence respiratory burst [30].
Moreover, L-selectin signalling can lead to increased bacterial
killing capacity [26,33].
In the current experiment, the presence of monoclonal anti-
bodies to L-selectin did not alter the pro-inflammatory
response to septic stimuli as reflected by circulating levels of
TNF-α or IL-6 measured up to 72 h after bacterial challenge.
These results differ from previous studies where anti-adhesion
therapy with monoclonal antibodies to E- and L-selectin has
been reported to increase the release of pro-inflammatory
cytokines IL-6, IL-8, and TNFR-1 in a baboon model of sepsis
[18]; however, this previous study differs from the current one
in its protocol. Twelve hours after the initial bacterial challenge,
anti-adhesion therapy in this study was followed by the
administration of killed bacteria [18], which itself causes a
sepsis-like condition.
Organ-specific measurements, such as gas exchange, wet
lung weight and liver transaminase levels, showed that there
were no negative side effects of anti-L-selectin antibody
administration. The only difference in organ specific function
between placebo and anti-L-selectin antibody was found in
serum creatinine levels measured at one time point only. Fur-
thermore, neither macroscopic pathology, histopathology nor
urine volume revealed any differences in renal injury or function
between the groups (data not shown). Hemodynamically, the
mean arterial blood pressure at 32 h, but at no other time
point, was significantly lower in the anti-L-selectin group than
in the placebo group. However, there were no differences in
SVR or cardiac output at this time point. This resembles
results found in an ovine ischemia/reperfusion model in which
administration of an ovine anti-L-selectin reduced arterial
blood pressure almost to normal levels [30]. Furthermore, the
general cardiovascular response as well as the resuscitative
fluid requirements were similar in both groups.
The lack of a negative effect of the anti-L-selectin antibody on
the immunoinflammatory response in the current experiment is
in concordance with in vitro studies using this antibody. These
in vitro experiments showed that the anti-L-selectin antibody
impaired neither PMN phagocytosis (of FITC-labeled
opsonized E. coli) nor respiratory burst (measured by oxidation
of fluorogenic substrate using flow cytometry). Similarly, the
anti-L-selectin antibody did not interfere with endotoxin
induced IL-1 synthesis by monocytes (all in vitro data on file at
Scil Biomedicals, Martinsried, Germany). Moreover, in vivo
evidence suggests that anti-L-selectin therapy even has bene-
ficial effects in endotoxemic models. In mice lacking cell sur-
face expression of L-selectin, death from endotoxin is largely
prevented [34] and anti-L-selectin therapy prevents endotoxin-
induced leukocyte sequestration [35].
In contrast to these positive reports using anti-L-selectin
approaches, an antibody to CD18 has been shown to
increase susceptibility to infection with Pseudomonas aerugi-
nosa  in rabbits [36]. The explanation for this discrepancy
between therapies directed at L-selectin versus CD18 may be
that CD18 is directly involved in neutrophil phagocytosis, as
CD18 deficient leukocytes fail to increase phagocytic function
in response to stimulation [37]. Thus, our current in vivo find-
ings not only corroborate the results of in vitro studies show-
ing that blockade of L-selectin did not inhibit leukocyte
function, but also show that anti-L-selectin seems to improve
bacterial clearance. The exact mechanism and the clinical rel-
evance of the improved bacterial clearance after L-selectin
antibody administration are not known and will, therefore,
require further investigation.
Conclusion
Anti-L-selectin (antibody) therapy did not adversely affect sur-
vival, promote organ dysfunction or result in major side effects.
This fact and the improved bacterial clearance rate observed
in the baboons receiving anti-L-selectin antibodies indicate
that septic episodes occurring during anti-L-selectin therapy
are probably not dangerous. These findings are particularly
important as sepsis is a common complication in the post-trau-
matic and post-hemorrhage course.
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